Pregled bibliografske jedinice broj: 547419
Observational study of patients switched to the fixed travoprost0, 004/timolol 0, 5% combination in Croatia
Observational study of patients switched to the fixed travoprost0, 004/timolol 0, 5% combination in Croatia // Methods and findings in experimental and clinical pharmacology, 32 (2010), 8; 593-598 doi:10.1358/mf.2010.32.8.1501437 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 547419 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Observational study of patients switched to the fixed travoprost0, 004/timolol 0, 5% combination in Croatia
(Observational study of patients switched to the fixed travoprost 0, 004%/timolol 0, 5% combination in Croatia)
Autori
Mandić, Zdravko ; Novak-Lauš, Katia ; Bojić, Lovre ; Popović Suić, Smiljka ; Maričić Došen, Vukosava ; Pelčić, Goran ; Dobutović, Davor ; Biuk, Dubravka ; Kovačić, Željko ; Pavan, Josip
Izvornik
Methods and findings in experimental and clinical pharmacology (0379-0355) 32
(2010), 8;
593-598
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
travoprost; timolol
Sažetak
The purpose of this study was to assess both the benefits of a 3-month travoprost 0.004%/timolol 0.5%fixed combination (trav/tim) regimen in comparison with previous medications for the control of intraocular pressure (IOP) and the tolerability of these drug regimens in glaucoma patients. An observational, non-interventional, open-label study of 406 eyes with primary open angle glaucoma and ocular hypertension was thus undertaken. One drop of trav/tim fixed combination was administered in the evening for 3 months. Patients were divided into five groups according to previous drug regimens: timolol 0.5% monotherapy ; betaxolol 0.5% monotherapy ; latanoprost 0.005% monotherapy ; travoprost 0.004% monotherapy ; and dorzolamide 2%/timolol 0.5% fixed combination. Upon medication substitution, the trav/tim fixed combination provided better IOP control and tolerability in all five patient groups. At the 3-month follow up, the mean IOP changes from previous therapy were as follows: 5.2 ± 2.7 mmHg (20.8% change) in timolol 0.5% group ; 5.7 ± 2.2 mmHg (22.5% change) in betaxolol 0.5% group ; 3.8 ± 2.6 mmHg (24.5% change) in latanoprost 0.005% group ; 4.4 ± 2.8 mmHg (20% change) in travoprost 0.004% group ; and 3.4 ± 4.1 mmHg (14.5% change) in dorzolamide 2%/timolol 0.5% fixed combination group. The difference between baseline and trav/tim combination patient satisfaction at the 3-month follow-up was significant. Thus, the trav/tim fixed combination provided better IOP control and tolerability than previous mono- or polytherapies. •
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
KBC "Sestre Milosrdnice"
Profili:
Katia Novak-Lauš
(autor)
Smiljka Popović-Suić
(autor)
Željko Kovačić
(autor)
Josip Pavan
(autor)
Davor Dobutović
(autor)
Goran Pelčić
(autor)
Josip Pavan
(autor)
Dubravka Biuk
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE